Navigating Uncertainty: A Review of Health Economic Evaluations

The Importance of Uncertainty Assessment

Health Economic Evaluations (HEEs) play a crucial role in reimbursement decisions, particularly in the realm of healthcare technologies. However, these evaluations are often fraught with uncertainty, posing significant challenges to decision-makers. The assessment of uncertainty is a cornerstone of these evaluations, helping to gauge the robustness of results and the potential consequences of uncertainty related to decisions. Yet, there is currently no comprehensive overview of the methods used for uncertainty assessment in HEEs.

Exploring the Methods of Uncertainty Assessment

A recent review aimed to fill this gap, exploring the various methods used for uncertainty assessment in model-based HEEs. The review identified a total of 80 different methods for assessing uncertainty: 30 for identification, 28 for analysis, and 22 for communication. These methods cater to different sources of uncertainty, with most identification methods developed to assess related concepts like validity, model quality, and relevance.

This review aids analysts and decision-makers by guiding them to choose suitable uncertainty assessment techniques based on their specific needs and the overall assessment purpose. However, it also highlights the need for more precise terminology and guidance on using these methodologies.

In conclusion, assessing uncertainty is crucial in HEEs. The paper below offers a comprehensive review of the methods the industry is currently using. Nevertheless, additional work is necessary to both clarify language and provide direction on the application of these methodologies.

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

April 21, 2025April 20, 2025 Rene Pretorius

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

April 21, 2025 João L. Carapinha

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

April 18, 2025April 18, 2025 Rene Pretorius

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology